

**NATH & ASSOCIATES PLLC**

*Attorneys at Law*

1030 Fifteenth Street, N.W.

Sixth Floor

Washington, D.C. 20005-1503

TELEPHONE: (202) 775-8383

(202) 775-9393

FACSIMILE: (202) 775-8396

(202) 822-9409

E-Mail: [ip@nathlaw.com](mailto:ip@nathlaw.com)

Web: [www.nathlaw.com](http://www.nathlaw.com)

*Gary M. Nath (DC, NJ)*

*Harold L. Novick (DC, MD)*

*Suet M. Chong (DC)*

*Irvin A. Lavine (DC), Retired\**

*Donald M. Sandler (MD), Retired\**

*Patent, Trademark and Copyright Causes  
Unfair Competition, Trade Secrets,  
Licensing and Litigation*

*\*Practice limited to Matters and  
Proceedings before Federal Courts and  
Agencies; not Admitted in DC*

*Todd L. Juneau (DC, IL)*

*Gregory B. Kang (DC, NJ)*

*Michelle L. Hartland (VA)\**

*Scott F. Yarnell (MD)\**

*Lee C. Heiman (CA)\**

*Jerald L. Meyer (VA)\**

*Paul A. Sacher (MD)\**

*David R. Murphy (VA)\**

*Marvin C. Berkowitz (GA)\**

*Tanya E. Jankovic (MD)\**

*Joshua B. Goldberg (VA)\**

*David H. Milligan (VA)\**

*Alvin E. Tanenholtz \*\**

*Charles D. Niebylski, Ph.D.\*\**

*Deborah H. Yellin\*\**

*\*\* Registered Patent Agent: not Admitted in DC*

**FORM PTO-1082**

**TRANSMITTAL FOR NEW U.S. PATENT APPLICATION**

Honorable Commissioner of  
Patents and Trademarks  
Washington, D.C. 20231

Re: New U.S. Patent Application

For: NOVEL INCLUSION COMPLEXES OF A HIGH POTENT OPIOID  
PEPTIDE, PHARMACEUTICAL COMPOSITIONS AND METHOD OF  
TREATMENT

Inventor(s): (1) Anil Kumar DWIVEDI, (2) Madhu KHANNA,  
(3) Wahajul HAQ, (4) Ram RAGHUBIR, (5) Sudhir  
SRIVASTAVA, (6) Puvvada SRI (7) Ramchandra  
MURTHY, (8) Onkar Prasad ASTHANA, (9)  
Jagdishwar Sahay Srivastava, (10) Satyawan  
SINGH

Attorney Docket: 82239

Sir:

Attached hereto is the application identified above, includ-  
ing:

31 Pages Application Consisting of:  
17 Pages of Textual Specification  
2 Pages of 15 Claims  
1 Abstract of the Disclosure  
11 Sheets of drawings.  
X Unexecuted Inventor's Declaration

The Government filing fee\* is calculated as follows:

Total Claims . . . . .	<u>15</u> - <u>20</u> = <u>5</u>	x \$18.00 =	\$ <u>90.00</u>
Independent Claims . . . . .	<u>2</u> - <u>3</u> = <u>0</u>	x \$78.00 =	\$ <u>0.00</u>
Base Fee . . . . .			\$ <u>690.00</u>
Multiple Dependent Claim Fee (\$260.00) . . . . .			\$ <u>0.00</u>
Subtotal . . . . .			\$ <u>690.00</u>

**TOTAL FILING FEE**

\$690.00


JC586 U.S. PTO  
09/537088



- ☐ Preliminary Amendment reducing filing fees is submitted herewith
- ☐ \*Reduced by one-half, as applicant(s) is/are a "small entity".  
A Declaration Claiming Small Entity Status:
- ☐ is submitted herewith
- ☐ will be filed at a later date.
- ☐ Foreign priority is claimed under 35 U.S.C. § 119 from  
\_\_\_\_\_ Patent Application(s) No.  
\_\_\_\_\_ dated \_\_\_\_\_.
- ☐ Priority document(s) will be submitted at a later date.
- ☐ Priority document(s) is/are submitted herewith.
- ☒ Executed Declaration(s) will be submitted at a later date pursuant to 37 CFR § 1.41 and § 1.53, with an appropriate surcharge under 37 CFR § 1.16(e).
- ☒ Formal drawing(s) is/are attached.
- ☐ Formal drawing(s) will be submitted at a later date.
- ☐ Assignment document(s) is/are submitted herewith; the recordation fee of \$40.00 per document is enclosed herewith.
- ☐ A Verified Translation will be submitted at a later date.
- ☒ No payment is enclosed at this time. Full payment will be made when the executed Declaration is submitted.
- ☐ Submitted herewith is a check in the amount of \$\_\_\_\_\_. The Commissioner is hereby authorized to charge any deficiency or credit any excess to Deposit Account No. 14-0112.

Respectfully submitted,

NATH & ASSOCIATES

  
Harold L. Novick  
Registration No. 26,011

Date: March 29, 2000

NATH & ASSOCIATES  
1030 Fifteenth Street, N.W., Sixth Floor  
Washington, D.C. 20005  
(202)-775-8383  
HLN/kb

03/29/00  
jc644 U.S. PTO

BOX PATENT APPLICATION  
Attorney Docket No. 82239

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of  
Anil Kumar DWIVEDI et al.  
Serial No. Not Yet Assigned  
Filed: March 29, 2000

JC586 U.S. PTO  
09/537088  
03/29/00

For: NOVEL INCLUSION COMPLEXES OF A HIGH POTENT OPIOID PEPTIDE,  
PHARMACEUTICAL COMPOSITIONS AND METHOD OF TREATMENT

TRANSMITTAL LETTER

The Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

Submitted herewith for filing in the U.S. Patent and Trademark  
Office is the following:

- (1) Transmittal Letter;
- (2) Transmittal For New U.S. Patent Application PTO form 1082-  
31 Pages Application Consisting of:
  - 17 Pages of Textual Specification
  - 2 Pages of 15 Claims
  - 1 Abstract of the Disclosure
  - 11 Sheets of drawings.
- (3) Unexecuted Inventor's Declaration; and
- (4) Early Notification Serial Number Postcard.

Respectfully submitted,

NATH & ASSOCIATES

By:

*Harold L. Novick*  
Harold L. Novick  
Registration No. 26,011

Date: March 29, 2000  
NATH & ASSOCIATES  
1030 Fifteenth Street, N.W., Sixth Floor  
Washington, D.C. 20005  
(202) -775-8383  
HLN/kb

## **Field of the invention ,**

The present invention relates to novel inclusion complexes of a high potent opioid peptide, Tyrosyl-D-alanyl-glycyl-N-methylphenylalanyl-glycyl-isopropylamide with cyclodextrin derivative. More particularly, the invention relates to Tyrosyl-D-alanyl-glycyl-N-methylphenylalanyl-glycyl-isopropylamide with cyclodextrin derivatives such as beta-cyclodextrin, hydroxypropyl-beta cyclodextrin, hydroxyethyl-beta-cyclodextrin. Dimethyl-beta cyclodextrin. The invention also relates to a process for the preparation of pharmaceutical compositions containing the inclusion complexes of opioid peptide and the use thereof in the treatment of alleviating pain and acute inflammation, which can be used as a substitute for narcotic analgesics.

## **Background of the invention**

There exists a constant need for preparing novel centrally acting agents which can be utilized as substitute for the narcotic analgesics, currently being used, having improved biopharmaceutical properties such as low toxicity, lesser tolerance, longer duration of action and least abuse potential. The development of the peptide as drug is restricted due to its poor oral efficacy. In view of this, it is essential to develop orally active formulations. There has been tremendous emphasis on the development of innovative strategies for the oral delivery of peptide based drugs, with increased water solubility, dissolution, bioavailability and improved oral efficacy.

### Prior Art

Soon after the discovery of enkephalin by Hug<sup>7</sup>es et. Al [Huges et. Al, Nature 258, 577 (1975)], an endogenously occurring pentapeptide with morphinomimetic activity, structure activity relationship studies were undertaken world-wide with the objective of getting a synthetic congener that would be clinically acceptable pain killer as substitute to morphine. Since the analgesia evoked by enkephalins was only weak and transient following their administration by intra-cerebral route, greater emphasis was laid on the structural modification of the penta peptide which would lead to the peptide(s) capable of eliciting profound analgesis even after their systemic administration.

The two best enkephalin analogues that had undergone fairly extensively clinical studies so far, are the Sandoz compound FK -33-824 [Tyr-D-Ala-Gly-Met(o)-01 and the Lilly compound met-keohamid (Tyr-D-Ala-Gly-Phe-MeMet-NH<sub>2</sub>). [Von Graffenreid, B., del Pozo, E., Roubicek, J., Krebs, E., Poldinger W., Burmeister, P. and Kerp, L., Nature, 272, 729 (1978) and Frederickson, R.C.A., Smithwick, E. L., Shuman, R. and Bemis, K.G., Science, 211, 603, (1981) Frederickson, R.C.A.. In 'Opioid Peptides: Molecular Pharmacology, Bio synthesis and analysis" Rapaka, R.S. and Hawks, R. L. eds. NIDA Research Monograph, 70 367. (1986) FK-33-824 gave only slight preference for  $\mu$ -receptors and met-kephamid was found essentially non-elective for  $\mu$  and  $\delta$  receptors. A strong analgesic effect was exerted by both the compounds by systemic route of administration. However, due to a number of serious side effects produced by FK -33-824 therefore it was no longer pursued for further developments as candidate analgesic drug. Relatively fewer side effects were observed with met-kephamid, but due to its hypotensive effect this compound was also finally abandoned.

Another enkephalin analogs Tyr-D-Met-Gly-Phe-Pro-NH<sub>2</sub> [Flodes, J., torok, K., Szekeley, J.I., Borvenderg, J., Karezag, I., Tolna, J., Marosfi, S., Varadi, A., Gara, A., Ronai, A.Z. and Szilagyi, G. *Life Sciences* 33, Supp. 1, 769 (1983)] and Tyr-Arg-Gly-Phe(p-NO<sub>2</sub>)-Pro-NH<sub>2</sub> (BW-443C) [Follenfant, R.J., Hardy, G.W., Lowe, L.A., Schneider, C. and Smith, T.W. *Br. J. Pharmacol.* 93, 85, (1988) and Kriss, M.G., Gralla, R.J., Clark, R.A., Tyson, L.B. and Groshen, S., *J. Clin. Oncol.*, 6, 663, (1988)] were also shown to be more potent analgesic than morphine but due to number of side effects these compounds were also dropped after initial clinical trials. Similarly, structure activity relationship studies were undertaken in our laboratory and an enkephalin analog Tyr-D-Ala-Gly-MePhe-Gly-NHC<sub>3</sub>H<sub>7</sub> [Raghubir, R., Patnaik, G.K., Sharma, S.D., Mathur, K.B. and Dhawan B.N., In recent progress in chemistry and biology of centrally acting peptides. Dhawan B.N. and Rapaka R.S. eds., 167, (1988) and Indian Patent no. 173568 19.10.1989] synthesised earlier in our laboratory and found to be more potent than morphine following systemic administration. This is a highly  $\mu$ -receptor selective in central and peripheral assay and produces highly profound and long lasting analgesia. (C. Nath, G.K. Patnaik, W. Haq, K.B. Mathur, R.C. Srimal, B.N. Dhawan and F. Porreca. *Pharmacological Research.*, 31, 269-273, 1995) The compound and its process for the synthesis was first disclosed in Indian patent [Indian Patent no. 173568 19.10.1989]. Subsequently chronic and subacute toxicity studies on this compound were carried out and it is now disclosed that this compound is safe and did not produce any noticeable toxic side effects. This compound was also studied for their addiction liabilities and tolerance and found to elicit significantly reduced tolerance and addiction properties as compared to morphine. The compound is virtually devoid of any major CNS effects like sedation and respiratory depression; it is also virtually devoid of any significant cardiovascular effects. Therefore, this compound has a potential as centrally active analgesic agent, which can be used as a substitute to narcotic analgesics (Morphine and related substances). However, this compound upon oral administration produced poor response and extremely high dose is required to obtain similar magnitude of response as observed after parenteral administration owing to its decomposition and poor absorption. The oral efficacy of the therapeutic agents is considered to be highly desirable, therefore, inspite of a profound analgesia and favourable pharmacological effect and almost devoid of toxic effects, the development of the peptide as drug is restricted due to its poor oral efficacy. In view of this, it is essential to develop orally active formulations.

There has been tremendous emphasis on the development of innovative strategies for the oral delivery of peptide based drugs, (A Fasano. (1998) *TIBTECH.*, 16, 152-157) with increased water solubility, dissolution, bioavailability and improved oral efficacy (Z. Shao, 1992). Cyclodextrins are reported in the literature that they increase water solubility, dissolution, bioavailability and stability of compound by forming inclusion complexes. [R. Krishnamoorthy and A. K. Mitra, *Pharma. Res.*, 9: 1157-1163 (1992)]. Recently it was reported in the literature that the  $\beta$ -cyclodextrin inclusion complex increase the half life of Leu-enkephalin from 45 min to 75 min in case of enzyme hydrolysis with leucine amino peptidase (W. J. Erwin., A. K. Dwivedi, P.A. Holbrook, and M. J. Dey, *Pharma Res.*, 11, 1994, 1698-1703). Therefore, the preparation of inclusion complex of peptides and other substances with cyclodextrin are reported in the literature. The advantage of binding substances into inclusion complexes with cyclodextrin is also known in other substances. US Patent No.4603123, 5840714 and 5855916 disclosed the increased therapeutic efficacy and reduced toxic effects of piroxicam, ibuprofen and acid base type drugs respectively.

### **Objects of the invention**

The main object of the present invention is to provide novel L-Tyrosyl-D-alanyl-glycyl-N-methylphenylalanyl-glycyl-isopropylamide: cyclodextrin complexes having significantly improved oral efficacy and prolonged duration of action.

Another object is to provide novel inclusion complexes that can be utilised as substitute for narcotic analgesics, said complexes having improved biopharmaceutical properties such as low toxicity, lesser tolerance, longer duration of action and least abuse potential.

Still another object is to provide novel L-Tyrosyl-D-alanyl-glycyl-N-methylphenylalanyl-glycyl-isopropylamide complexes with increased water solubility, dissolution, bioavailability and improved oral/transdermal efficacy.

Yet another object is to provide pharmaceutical compositions containing said novel inclusion complexes having improved analgesic activity with longer duration of activity and improved efficacy.

Still another object is to provide methods for the treatment of acute inflammatory conditions employing the said inclusion complexes.

### **Summary of the invention**

The above and other objects are realized by the present invention that provides novel inclusion complexes having improved analgesic property and longer duration of activity. The invention also provides pharmaceutical compositions containing said inclusion complexes and methods of treatment employing such inclusion complexes.

### **Detailed Description:**

Accordingly, the invention provides novel inclusion complexes having significantly improved oral efficacy and prolonged duration of action selected from the group consisting of highly potent opioid peptide of L-Tyrosyl-D-alanyl-glycyl-N-methylphenylalanyl-glycyl-isopropylamide with a cyclodextrin derivative wherein said derivative is selected from the group consisting of beta cyclodextrin, hydroxypropyl-beta cyclodextrin, dimethyl-beta cyclodextrin and hydroxyethyl-beta-cyclodextrin

In an embodiment, the invention provides cyclodextrin derivative selected from beta cyclodextrin, hydroxypropyl-beta cyclodextrin, dimethyl-beta cyclodextrin, hydroxyethyl-beta-cyclodextrin.

In yet another embodiment, the inclusion complex comprises L-Tyrosyl-D-alanyl-glycyl-N-methylphenylalanyl-glycyl-isopropylamide with beta,-cyclodextrin.

In still another embodiment, the inclusion complex comprises L-Tyrosyl-D-alanyl-glycyl-N-methylphenylalanyl-glycyl-isopropylamide with hydroxyethyl beta-cyclodextrin.

In yet another embodiment, the inclusion complex comprises L-Tyrosyl-D-alanyl-glycyl-N-methylphenylalanyl-glycyl-isopropylamide with hydroxypropyl beta-cyclodextrin.

In another embodiment, the inclusion complex comprises L-Tyrosyl-D-alanyl-glycyl-N-methylphenylalanyl-glycyl-isopropylamide with dimethyl beta-cyclodextrin.

In still another embodiment, the molar ratio between L-Tyrosyl-D-alanyl-glycyl-N-methylphenylalanyl-glycyl-isopropylamide and said cyclodextrin derivative is 1:5 to 2:1.

In yet another embodiment, the invention provides pharmaceutical compositions comprising a therapeutically effective amount of inclusion complex of L-Tyrosyl-D-alanyl-glycyl-N-methylphenylalanyl-glycyl-isopropylamide with beta-cyclodextrin having improved analgesic activity with longer duration of action as compared with the free peptide.

In yet another embodiment, the pharmaceutical composition has potential for clinical application as an analgesic.

In still another embodiment, the pharmaceutical composition is formulated in various physical forms such as tablets, injections, capsules.

The invention also provides methods for the treatment of acute inflammations and for alleviating pain comprising the step of administration of pharmaceutical composition containing the inclusion complex to a patient in need thereof.

In an embodiment, the inclusion complex is administered orally or transdermally or rectal route.

In yet another embodiment, the pharmaceutical composition exhibits significant analgesic activity with reduced dependence liability, respiratory depression, gastric irritation and sedation.

In another embodiment, the method for the treatment of acute inflammations and for alleviating pain, comprises oral administration of inclusion complex of L-Tyrosyl-D-alanyl-glycyl-N-methylphenylalanyl-glycyl-isopropylamide with beta-cyclodextrin.

In another embodiment, the method for the treatment of acute inflammations and for alleviating pain, comprises topical application of inclusion complex of L-Tyrosyl-D-alanyl-glycyl-N-methylphenylalanyl-glycyl-isopropylamide with beta cyclodextrin.

The L-Tyrosyl-D-alanyl-glycyl-N-methylphenylalanyl-glycyl-isopropylamide: cyclodextrin (1:2) complex of the invention is used for the oral delivery of the peptide as these complexes provide more protection to the peptide against the gastric environment. The L-Tyrosyl-D-alanyl-glycyl-N-methylphenylalanyl-glycyl-isopropylamide: cyclodextrin (1:1) complex is used for the transdermal delivery of the peptide as these complexes facilitate the transdermal permeation of the peptide.

## Methods of preparation

### TECHNICAL SOLUTION

The invention is illustrated by the following Examples which in no way represent a limitation thereof

#### EXAMPLE 1

##### **Preparation of L-Tyrosyl-D-alanyl-glycyl-N-methylphenylalanyl-glycyl-isopropylamide [Figure 1]:**

The penta-peptide was synthesised by solution phase method of peptide synthesis employing three plus two fragment condensation method or by step up chain elongation procedure. This compound was also prepared on solid support employing commercially available supports using either BOC or FMOC chemistry. The coupling reactions were performed by commonly available reagents adopting reported procedures. The out line of the process for the preparation of the penta-peptide has been disclosed in Indian Patent No. 173568 19.10.1989.

FIG. 2 shows Mass spectrum of L-Tyrosyl-D-alanyl-glycyl-N-methylphenylalanyl-glycyl-isopropylamide.

FIGS. 3 show NMR spectrum of L-Tyrosyl-D-alanyl-glycyl-N-methylphenylalanyl-glycyl-isopropylamide.

FIG. 4 shows DSC (differential scanning calorimetry) thermogram of L-Tyrosyl-D-alanyl-glycyl-N-methylphenylalanyl-glycyl-isopropylamide.

#### EXAMPLE 2

##### **Preparation of inclusion complex of L-Tyrosyl-D-alanyl-glycyl-N-methylphenylalanyl-glycyl-isopropylamide with beta-cyclodextrin**

###### **a) Procedure in aqueous medium**

Beta-cyclodextrin (1.135 g, 1.0 m mole) in water (25 ml) was heated to boiling temperature. L-Tyrosyl-D-alanyl-glycyl-N-methylphenylalanyl-glycyl-isopropylamide (0.568 g, 1.0 m mole) was added into this solution, vigorously stirred for 15 minutes and the mixture was cooled during stirring to a temperature between 0 degree and 5 degree centigrade. The obtained complex was dried in vacuum at the temperature of about 40 degree C. Inclusion complex (1.62 g, 95.1%) of L-Tyrosyl-D-alanyl-glycyl-N-methylphenylalanyl-glycyl-isopropylamide with beta-cyclodextrin was obtained in the form of a white powder in the molar ratio of 1:1.

Data on reaction yields, L-Tyrosyl-D-alanyl-glycyl-N-methylphenyl-alanyl-glycyl-isopropylamide content in the complex (determined theoretically and experimentally-spectrophotometric determination at the wavelength of 275 nm) are summarised in Table 1

Fig. 5 shows Differential scanning calorimetry (DSC thermogram) in the curve of the obtained product. There was not detected any endothermic transition for a melting point, characteristic of a physical mixture of L-Tyrosyl-D-alanyl-glycyl-N-methylphenylalanyl-glycyl-isopropylamide.

Fig. 6 shows NMR spectrum of the complex of L-Tyrosyl-D-alanyl-glycyl-N-methylphenylalanyl-glycyl-isopropylamide with beta-cyclodextrin.

FIG. 7 shows Mass spectrum of the complex of L-Tyrosyl-D-alanyl-glycyl-N-methylphenylalanyl-glycyl-isopropylamide with beta-cyclodextrin.

b) Procedure in a solvent mixture (methanol/water in the ratio 5:20)

Beta.-cyclodextrin (1.135 g; 1.0 m mole) was dissolved in water (25 ml) at a temperature of about 70 degree C. During stirring a solution of L-Tyrosyl-D-alanyl-glycyl-N-methylphenylalanyl-glycyl-isopropylamide (0.568 g; 1.0 m mole) in methanol (5 ml) was added. It was stirred for another 5 minutes, the solvents were evaporated and the obtained complex was dried in vacuum at a temperature about 40 degree C. Inclusion complex (1.59 g, 93.4%) of L-Tyrosyl-D-alanyl-glycyl-N-methylphenylalanyl-glycyl-isopropylamide with beta-cyclodextrin was obtained in the form of a white powder in the molar ratio of 1:1.

Differential scanning calorimetry, mass and NMR spectrum showed the same results as in the process for preparing the inclusion complex in an aqueous medium.

### EXAMPLE 3

Preparation of inclusion complex of L-Tyrosyl-D-alanyl-glycyl-N-methylphenylalanyl-glycyl-isopropylamide with beta-cyclodextrin

a) Procedure in aqueous medium

Beta.-cyclodextrin (1.135 g; 1.0 m mole) in water (25 ml) was heated to boiling temperature, into the boiling solution of L-Tyrosyl-D-alanyl-glycyl-N-methylphenyl-alanyl-glycyl-isopropylamide (0.284 g; 0.5 m mole) was added, vigorously stirred for 15 minutes and the mixture was cooled during stirring to a temperature between 0 degree and 5 degree C. The obtained complex was dried in vacuum at the temperature of about 40 degree C. Inclusion complex (1.33 g; 93.7%) of L-Tyrosyl-D-alanyl-glycyl-N-methylphenyl-alanyl-glycyl-isopropylamide with beta.-cyclodextrin was obtained in the form of a white powder in the molar ratio of 1:2.

Data on reaction yields, L-Tyrosyl-D-alanyl-glycyl-N-methylphenylalanyl-glycyl-isopropylamide content in the complex (determined theoretically and experimentally-spectrophotometric determination at the wavelength of 275 nm) are summarised in Table I

Fig. 8 shows Differential scanning calorimetry (DSC thermogram) in the curve of the obtained product there was not detected any endothermic transition for a melting point, characteristic of a physical mixture of L-Tyrosyl-D-alanyl-glycyl-N-methylphenylalanyl-glycyl-isopropylamide/beta-cyclodextrin.

Fig 9 shows NMR spectrum of the complex of L-Tyrosyl-D-alanyl-glycyl-N-methylphenylalanyl-glycyl-isopropylamide with beta-cyclodextrin.

b) Procedure in a solvent mixture (methanol/water in the ratio 5:20)

Beta.-cyclodextrin (1.135 g; 1.0 m mole) was dissolved in water (25 ml) at a temperature of about 70 degree C. L-Tyrosyl-D-alanyl-glycyl-N-methylphenylalanyl-glycyl-isopropylamide (0.284 g; 0.5 m mole) in methanol (5 ml) was added and stirred for another 5 minutes. The solvents were evaporated and the complex obtained was dried in vacuum at a temperature about 40 degree C. Inclusion complex (1.36 g; 95.8%) of L-Tyrosyl-D-alanyl-glycyl-N-methylphenylalanyl-glycyl-isopropylamide with beta.-cyclodextrin was obtained in the form of a white powder in the molar ratio of 1:2.

Differential scanning calorimetry and NMR spectrum showed the same results as in the process for preparing the inclusion complex in an aqueous medium.

#### EXAMPLE 4

Preparation of inclusion complex of L-Tyrosyl-D-alanyl-glycyl-N-methylphenylalanyl-glycyl-isopropylamide with hydroxypropyl-beta.-cyclodextrin

a) Procedure in methanolic medium

L-Tyrosyl-D-alanyl-glycyl-N-methylphenylalanyl-glycyl-isopropylamide (0.568 g; 1.0 m mole) was added to a solution of hydroxypropyl-beta-cyclodextrin (1.38 g; 1.0 m mole) in methanol (25 ml) and the obtained solution was stirred for another 5 minutes at room temperature. Methanol was then evaporated and the obtained complex was dried in vacuum at the temperature of 40 degree C. Inclusion complex (1.82g; 93.4%) of L-Tyrosyl-D-alanyl-glycyl-N-methylphenylalanyl-glycyl-isopropylamide with hydroxypropyl-beta-cyclodextrin was obtained in the form of a white powder in the molar ratio of 1:1.

Data on reaction yields, L-Tyrosyl-D-alanyl-glycyl-N-methylphenylalanyl-glycyl-isopropylamide content in the complex (determined theoretically and experimentally-

spectrophotometric determination at the wavelength of 275 nm) of the complex formed are summarised in Table I.

Fig. 10 shows differential scanning calorimetry (DSC thermogram)

Fig. 11 shows NMR spectrum of the complex of L-Tyrosyl-D-alanyl-glycyl-N-methylphenylalanyl-glycyl-isopropylamide with hydroxypropyl-beta-cyclodextrin.

b) Procedure in aqueous medium

Hydroxypropyl-beta-cyclodextrin (1.38 g; 1.0 mmole) was dissolved in water (40 ml) and the obtained solution was heated to the temperature of 70 degree C and L-Tyrosyl-D-alanyl-glycyl-N-methylphenylalanyl-glycyl-isopropylamide (0.568 g; 1.0 mmole) was added. It was vigorously stirred for another 15 minutes and then the solution was filtered. The filtrate was frozen in liquid nitrogen and lyophilised. Inclusion complex (1.81g, 92.9 %) of L-Tyrosyl-D-alanyl-glycyl-N-methylphenylalanyl-glycyl-isopropylamide with hydroxypropyl-beta-cyclodextrin was obtained in the form of a white powder in the molar ratio of 1:1.

Differential scanning calorimetry and NMR spectrum showed the same results as in the process for preparing inclusion complex in the methanolic medium.

### EXAMPLE 5

Preparation of inclusion complex of L-Tyrosyl-D-alanyl-glycyl-N-methylphenylalanyl-glycyl-isopropylamide with hydroxyethyl-beta-cyclodextrin

a) Procedure in methanolic medium

L-Tyrosyl-D-alanyl-glycyl-N-methylphenylalanyl-glycyl-isopropylamide (0.568 g; 1.0 mmole) was added to a solution of hydroxyethyl-beta-cyclodextrin (1.44 g; 1.0 mmole) in methanol (10 ml) and the obtained solution was stirred for another 5 minutes at room temperature. Methanol was then evaporated and the obtained complex was dried in vacuo at the temperature of 40 degree C. Inclusion complex (1.87 g; 93.1 %) of L-Tyrosyl-D-alanyl-glycyl-N-methylphenylalanyl-glycyl-isopropylamide with hydroxyethyl-beta-cyclodextrin was obtained in the form of a white powder in the molar ratio of 1:1.

Differential scanning calorimetry and NMR spectrum showed the formation of inclusion complex

b) Procedure in aqueous medium

Hydroxyethyl-beta-cyclodextrin (1.44 g; 1.0 mmole) was dissolved in water (40 ml). The obtained solution was heated to the temperature of 70 degree C. and L-Tyrosyl-D-alanyl-glycyl-N-methylphenylalanyl-glycyl-isopropylamide (0.568 g; 1.0 mmole) was added. It was vigorously stirred for another 15 minutes and then the solution was filtered. The filtrate was

frozen in liquid nitrogen and lyophilized. Inclusion complex (1.89 g, 94.1 %) of L-Tyrosyl-D-alanyl-glycyl-N-methylphenylalanyl-glycyl-isopropylamide with hydroxyethyl- $\beta$ -cyclodextrin was obtained in the form of a white powder in the molar ratio of 1:1. Differential scanning calorimetry and NMR spectrum showed the formation of inclusion complex.

TABLE I

Reaction yield, L-Tyrosyl-D-alanyl-glycyl-N-methylphenylalanyl-glycyl-isopropylamide content in the complex for inclusion complex of L-Tyrosyl-D-alanyl-glycyl-N-methylphenylalanyl-glycyl-isopropylamide with different derivatives of  $\beta$ -cyclodextrin.

Inclusion complex	Reaction yield (%)	% Content of L-Tyrosyl-D-alanyl-glycyl-N-methylphenylalanyl-glycyl-isopropylamide in the complex
Beta-cyclodextrin (1:1)	95.1	97.2
Beta-cyclodextrin (1:2)	93.7	92.88
hydroxypropyl-beta-cyclodextrin (1:1)	93.4	98.7
hydroxyethyl-beta-cyclodextrin (1:1)	93.1	97.5

#### EXAMPLE 6

30 days toxicity study of L-Tyrosyl-D-alanyl-glycyl-N-methylphenylalanyl-glycyl-isopropylamide in rat and rhesus monkey by subcutaneous route.

Compound L-Tyrosyl-D-alanyl-glycyl-N-methylphenylalanyl-glycyl-isopropylamide dissolved in saline was given daily by subcutaneous route to groups of rats ( $n=10$  males and 10 females in each group) and rhesus monkeys ( $n=2$  males and 2 females in each group) once daily for 30 consecutive days. The dose levels used in rats were 0.0, 7.5, 15.0 and 30.0 mg/kg and in monkeys 0.0, 3.75, 7.5 and 15 mg/kg. Dose levels were selected on the basis of rat ED of 3.0 mg/kg and extrapolation thereof in the monkey.

A careful general inspection of the animals was done at least once each day. Cage-side observations included changes in skin and fur, eyes and mucous membranes, general activity and behavior and also general signs of abnormal functioning of respiratory, circulatory, autonomic and central nervous system and somatomotor activity.

Body weights (weekly in rats, initial and day 30 in monkeys), daily food (rat and monkeys) and water (rat only) consumption and parameters of hematology, urinalysis and blood biochemistry of the animals was recorded. All the animals were sacrificed at the end of 30 days. Necropsy was performed and histopathological examination of all the important organs and tissues were done.

Urinalysis included the recording of colour, specific gravity reaction (pH) and testing for sugar, acetone, urobilinogen, bilirubin, and albumin and occult blood. Microscopic examination of urinary sediment was done for the presence of epithelial cells, WBCs, RBCs, casts, crystals and other abnormal constituents.

The hematological examinations included hemoglobin, T-RBC count, mean corpuscular hemoglobin concentration, mean corpuscular volume, total leukocyte count, packed cells volume, mean corpuscular volume, platelet counts, differential leukocyte counts, erythrocyte sedimentation rate (monkeys only) and prothrombin time test (monkeys only).

Biochemical estimations in blood done at day 30 in rat, and day 0 and 30 in monkeys included glucose, creatinine, urea nitrogen, sodium, potassium, SGPT (ALT), alkaline phosphatase (ALP), bilirubin, cholesterol, total serum proteins, albumin and globulin.

During necropsy examination of the external surface of the body, all orifices, and the cranial, thoracic and abdominal cavities and their contents was performed. A thorough naked eye examination of size, shape, surface, colour, contours etc of all the important organs and tissues was done. Liver, kidneys, adrenals, brain, heart, lungs, spleen and gonads were weighed, and their relative weights were also calculated.

All the above mentioned organs, and representative pieces from skin, trachea, thyroid, different parts of the GIT, pancreas, urinary bladder, mammary glands and whole eyes were preserved in 10% buffered formalin till they were processed for paraffin embedding and sectioning.

Representative places from all the preserved organs and tissues were processed for paraffin embedding. Four to six micrometer thick sections are cut and stained by haematoxylin and eosin according to standard methods for microscopic examination.

The animals continued to remain active and healthy throughout the period of experimentation. Animals of both drug treated and control groups showed uniform (rats) or irregular (monkeys) trends of gain in body weight. The laboratory investigations showed some minor incidental variations but there was no indication of drug induced damages in the various urinalyses, hematological and bloods biochemical values. Also, necropsy (including

absolute and relative organ weights of important organs and histopathological examinations did not reveal any sign of target organ toxicity.

Compound L-Tyrosyl-D-alanyl-glycyl-N-methylphenylalanyl-glycyl-isopropylamide was thus found safe in rats and rhesus monkeys in the 30-day toxicity study by subcutaneous route at the dose levels mentioned above.

#### EXAMPLE 7

Alleviation of pain:

Analgesia was measured by tail flick latencies (t.f.l.) assay in rats. (D'Amour, F. E and Smith, D. L., J. Pharmacol. Exp. Ther. 72,74-79, 1941) The test required determination of tail flick latencies to heat stimulus. The basal tail flick latencies were determined twice at 10 min interval and averaged to obtain single pre drug latency. An increase in the latency by 100% or more was indicative of analgesic state of animal. A cut-off time of 10 seconds was used to avoid damage to the tail skin.

The test compounds were administered (subcutaneously or per oral) in graded dose in groups of 8-10 rats each. Then tail flick latency was determined every 10 minutes till it was near the pre drug level. Percent of animals exhibiting analgesia was determined at each dose level of various compounds and the ED<sub>50</sub> along with 95% fiducial limits was calculated [Table 2] by prohibit analysis (Finney, 1971), The duration of analgesic effect was determined at the peak effect. The analgesia lasted for 5-6 hours after oral administration.

TABLE 2

Compound/Formulation	ED <sub>50</sub> (mg/Kg)	
	S.C. route	P. O. route
L-Tyrosyl-D-alanyl-glycyl-N-methylphenylalanyl-glycyl-isopropylamide	2.58	22.30
L-Tyrosyl-D-alanyl-glycyl-N-methylphenylalanyl-glycyl-isopropylamide beta CD complex (1:2)	4.45 (equivalent to 0.89 mg of compound)	54.23 (equivalent to 10.84 mg of compound)

It is evident from above table that the ED<sub>50</sub> of beta CD complex is about one third than the compound L-Tyrosyl-D-alanyl-glycyl-N-methylphenylalanyl-glycyl-isopropylamide by subcutaneous route and was one half by oral route. The LD<sub>50</sub> of the compound L-Tyrosyl-D-alanyl-glycyl-N-methylphenylalanyl-glycyl-isopropylamide is 1000 mg/Kg *i.p.*, and that of the complex is > 10,000 mg/kg P. O. in mice.

### EXAMPLE 8

#### Anti-inflammatory action

Anti-inflammatory action was measured *in vivo* by the inhibition of oedema caused by carrageenin. Rats were given 250/500 mg/kg of the test substance 1 hour before the injection of 0.1 ml 1% carrageenin suspension. The inhibition of the formed oedema was measured 3 hours after injecting carrageenin. [Table 3]

TABLE 3

Measurement of anti-inflammatory action *in vivo* at the dosages of 500/250 mg/kg of the active substance applied per orally substance

	Dose (p.o.) (mg/kg)	Anti-inflammatory action (210 min)
L-Tyrosyl-D-alanyl-glycyl-N-methylphenylalanyl-glycyl-isopropyl amide:beta CD complex (1:2)	250	4.0
L-Tyrosyl-D-alanyl-glycyl-N-methylphenylalanyl-glycyl-isopropyl amide:beta CD complex (1:2)	500	18.4
L-Tyrosyl-D-alanyl-glycyl-N-methylphenylalanyl-glycyl-isopropyl amide	50	19.6

The measurement *in vivo* of the anti-inflammatory action showed that the inclusion complex of L-Tyrosyl-D-alanyl-glycyl-N-methylphenylalanyl-glycyl-isopropylamide with beta cyclodextrin exhibited anti-inflammatory action.

### EXAMPLE 9

#### Effect on gastric mucous membrane

Effect of L-Tyrosyl-D-alanyl-glycyl-N-methylphenylalanyl-glycyl-isopropylamide and inclusion complex of L-Tyrosyl-D-alanyl-glycyl-N-methylphenylalanyl-glycyl-isopropylamide with beta cyclodextrin on gastric mucous membrane was measured in rats. Rats were fasted overnight and were given 100 mg/kg of the active substance orally. After 4 hours its effect on irritation of gastric mucous membrane and gastric ulceration, gastric juice volume and extent of free and total acid was determined. [Table 4].

Measurement of the effect of L-Tyrosyl-D-alanyl-glycyl-N-methylphenylalanyl-glycyl-isopropylamide:beta-cyclodextrin (1:1) on gastric mucous membrane

Dose (mg/kg)	Ulceration	Gastric Juice volume	Free acid	Total acid
100	-	- 23	+ 9.0	+ 10.0

The above data show that L-Tyrosyl-D-alanyl-glycyl-N-methylphenylalanyl-glycyl-isopropylamide bound into an inclusion complex with beta-cyclodextrin did not exhibit an irritating effect on gastric mucous membrane of the animals.

#### EXAMPLE 10

Preparation of tablets with 125 mg of active substance [inclusion complex (1:2)] of L-Tyrosyl-D-alanyl-glycyl-N-methylphenylalanyl-glycyl-isopropylamide with beta-cyclodextrin

Tablets of the following composition were prepared:

TABLE 5

Active constituent	Weight
L-Tyrosyl-D-alanyl-glycyl-N-methylphenylalanyl-glycyl-isopropylamide :beta cyclodextrin complex (1:2)	125 mg
lactose	70 mg
methyl cellulose	5 mg
magnesium stearate	2 mg

**Preparation of tablets:** The active substance was homogeneously stirred with additives. The mixture was sieved through a sieve and pressed into tablets on a rotating tableting machine. and the resulting tablet properly packed in a polythene lined blister type packing to avoid coming into contact with moisture before use.

#### EXAMPLE 11

Preparation of transdermal tapes of active substance (inclusion complex (1:1)) of L-Tyrosyl-D-alanyl-glycyl-N-methylphenylalanyl-glycyl-isopropylamide with beta-cyclodextrin

Polyvinyl alcohol (4 g) and polyvinylpyrrolidone (2 g) were taken in a beaker and stirred at 75° C, 120 ml ethyl alcohol (50% v/v) was slowly added into this to get a fine latex. L-Tyrosyl-D-alanyl-glycyl-N-methylphenylalanyl-glycyl-isopropylamide:beta- cyclodextrin complex (1:1) (1.8) g was taken & suspended in propylene glycol (2 ml) PEG 400 (0.5 ml),

poly propylene glycol (2 ml) and tritan X-100 (1.5 ml) by using sonicator. Polymer latex prepared in earlier step was transferred to it by continuous stirring and further stirred for 15 minutes. The hydrogel so formed was uniformly poured into a petri dish and allowed to dry. The next day a yellow coloured patch was obtained. This was covered with the plastic film and cut into the desired size. The patches so obtained were properly packed in a polythene lined blister type packing to avoid coming into contact with moisture before use.

## CLAIMS:

1. Inclusion complexes having significantly improved oral efficacy and prolonged duration of action selected from the group consisting of highly potent opioid peptide of L-Tyrosyl-D-alanyl-glycyl-N-methylphenylalanyl-glycyl-isopropylamide with a cyclodextrin derivative.
2. Inclusion complex as claimed in claim 1 the cyclodextrin derivative is selected from beta cyclodextrin, hydroxypropyl-beta cyclodextrin, dimethyl-beta cyclodextrin, hydroxyethyl-beta-cyclodextrin.
3. Inclusion complex as claimed in claim 1 comprising L-Tyrosyl-D-alanyl-glycyl-N-methylphenylalanyl-glycyl-isopropylamide with beta-cyclodextrin.
4. Inclusion complex as claimed in claim 1 comprising L-Tyrosyl-D-alanyl-glycyl-N-methylphenylalanyl-glycyl-isopropylamide with hydroxyethyl beta-cyclodextrin.
5. Inclusion complex as claimed in claim 1 comprising L-Tyrosyl-D-alanyl-glycyl-N-methylphenylalanyl-glycyl-isopropylamide with hydroxypropyl beta-cyclodextrin.
6. Inclusion complex as claimed in claim 1 comprising L-Tyrosyl-D-alanyl-glycyl-N-methylphenylalanyl-glycyl-isopropylamide with dimethyl beta-cyclodextrin.
7. Inclusion complex as claimed in claim 1 wherein the molar ratio between L-Tyrosyl-D-alanyl-glycyl-N-methylphenylalanyl-glycyl-isopropylamide and said cyclodextrin derivative is 1:5 to 2:1.
8. Pharmaceutical compositions comprising a therapeutically effective amount of inclusion complex of L-Tyrosyl-D-alanyl-glycyl-N-methylphenylalanyl-glycyl-isopropylamide with beta-cyclodextrin as claimed in claim 1 having

improved analgesic activity with longer duration of action as compared with the free peptide.

9. Pharmaceutical composition as claimed in claim 8 having potential for clinical application as an analgesic.
10. Pharmaceutical composition as claimed in claim 8 formulated in various physical forms such as tablets, injections, capsules.
11. A method for the treatment of acute inflammations and for alleviating pain comprising the step of administration of pharmaceutical composition containing the inclusion complex as claimed in claim 1 to a patient in need thereof.
12. A method as claimed in claim 11 wherein inclusion complex is administered orally or transdermally or rectal route.
13. A method as claimed in claim 11 wherein the pharmaceutical composition of claim 8 exhibits significant analgesic activity with reduced dependence liability, respiratory depression, gastric irritation and sedation.
14. A method as claimed in claim 11 for the treatment of acute inflammations and for alleviating pain, which comprises oral administration of inclusion complex of L-Tyrosyl-D-alanyl-glycyl-N-methylphenylalanyl-glycyl-isopropylamide with beta-cyclodextrin as claimed in claim 1.
15. A method for the treatment of acute inflammations and for alleviating pain, which comprises topical application of inclusion complex of L-Tyrosyl-D-alanyl-glycyl-N-methylphenylalanyl-glycyl-isopropylamide with beta cyclodextrin as claimed in claim 1.

## ABSTRACT

The invention provides novel inclusion complexes of highly potent opioid peptide of L-Tyrosyl-D-alanyl-glycyl-N-methylphenylalanyl-glycyl-isopropylamide with cyclodextrin, pharmaceutical preparations containing these inclusion complexes of L-Tyrosyl-D-alanyl-glycyl-N-methylphenylalanyl-glycyl-isopropylamide with cyclodextrin derivatives, said complexes being better soluble in water and having improved biopharmaceutical properties such as lesser toxicity, better analgesic action and non-addiction properties.

FIG. 1





FIG. 2


3-FEB-0 15:17








TEMPERATURE °C	HEAT FLOW EXOTHERMAL-->
100	0.00
150	0.00
200	0.00
250	0.00
300	0.00
350	0.00
400	0.00
450	0.00
500	0.00
550	0.00
600	0.00
650	0.00
700	0.00
750	0.00
800	0.00
850	0.00
900	0.00
950	0.00
1000	0.00



**FIG. 5**

FIG. 6



Current Data Parameters  
 NAME FE004  
 EXPNO 90  
 PROCNO 1


F2 - Acquisition Parameters  
 Date\_ 500000  
 Time 12.34  
 INSTRUM SDR200  
 PROBM 5 mm QNP 13  
 PULPROG zgpg30  
 F0 32768  
 SOLVENT D2O  
 NS 128  
 OS 2  
 SWH 411.842 Hz  
 FIDRES 0.25481 Hz  
 AQ 3.5246387 sec  
 RG 912.7  
 DM 121.600 usec  
 DE 6.00 usec  
 TE 305.0 K  
 D12 0.000200 sec  
 d13 0.000030 sec  
 PL9 58.00 dB  
 D1 1.0000000 sec  
 SFO1 200.1309396 MHz  
 MUCT 1H  
 PL1 -4.00 dB  
 P1 9.00 usec  
 DE 8.20 usec


F2 - Processing Parameters  
 SI 16384  
 SF 200.1299750 MHz  
 MOH EH  
 SSF 0  
 LB 0.30 Hz  
 GB 0  
 PC 1.00

10 NMR plot parameters  
 CX 20.00 cm  
 FIP 11.000 ppm  
 F1 2201.43 Hz  
 F2p -1.000 ppm  
 F2 -200.13 Hz  
 PPMCN 0.60000 ppm/cm  
 HZCM 120.07799 Hz/cm

FIG. 7


VCSS SPECTRUM Data File: 0IFB04D 4-FEB- 0 11:28  
 Sample: 82-205:BCD(1:1) DR M KHANNA  
 GC 1.4c BP: m/z 55.4047 Lu 0.00  
 Scan# 15 to 8)





**FIG. 8**

FIG. 9



Current Data Parameters  
NAME: FE004  
EPOCH: 100  
PLOT: 1

F2 - Acquisition Parameters

Date: 500000  
Time: 13.07  
INSTRUM: DDX200  
PRCS-C: 5 m Dual 13  
PLANS: 29CDP  
TQ: 32768  
SOLVENT: 020  
NS: 128  
DS: 2  
SWH: 4111.842 Hz  
FREQS: 0.125483 Hz  
AQ: 3.9846387 sec  
RG: 645.1  
DM: 121.600 usec  
DE: 6.00 usec  
TE: 305.0 K  
d12: 0.000200 sec  
d13: 0.000030 sec  
PL9: 58.00 dB  
D1: 1.00000000 sec  
SFC1: 200.1309437 MHz  
NUC1: 1H  
PL1: -4.00 dB  
P1: 9.00 usec  
DE: 6.00 usec

F2 - Processing Parameters

SC: 16384  
SF: 200.1299587 MHz  
MEM: EM  
SS3: 0  
LA: 0.30 Hz  
GB: 0  
PC: 0.80

10 MHz Plot Parameters

CX: 20.00 cm  
FIP: 11.000 ppm  
F1: 2201.43 Hz  
F2: -1.000 ppm  
F2: -200.13 Hz  
SPW: 0.60000 ppm/cm  
HZCM: 120.0797 Hz/cm

HEAT FLOW  
EXOTHERMAL-->




FIG. 10

[illegible]



## DECLARATION FOR PATENT APPLICATION

Atty Docket 82239

As a below-named inventor(s), I/we hereby declare that:

My/Our residence(s), post office address(es) and citizenship(s) is/are as stated below next to my/our name(s).

I/We believe I/we am/are the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter that is claimed, and for which a patent is sought on the invention entitled: **NOVEL INCLUSION COMPLEXES OF A HIGH POTENT OPIOID PEPTIDE, PHARMACEUTICAL COMPOSITIONS AND METHOD OF TREATMENT**

the specification of which: (check one)

☒ is attached hereto.

☐ was filed on \_\_\_\_\_, as Serial No. \_\_\_\_\_,  
and was amended on \_\_\_\_\_ (if applicable).

I/We hereby state that I/we have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I/We acknowledge the duty to disclose information which is material to the patentability of this application as defined by 37 CFR § 1.56.

I/We hereby claim foreign priority benefits under 35 U.S.C. § 119 of any foreign application(s) for patent or inventor's certificate listed below, and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Prior Foreign Applications:

(Application No.)	(Country)	(Day/Month/Year Filed)	Priority Claimed	
			<input type="checkbox"/> Yes	<input type="checkbox"/> No
_____	_____	____/____/____	<input type="checkbox"/>	<input type="checkbox"/>
(Application No.)	(Country)	(Day/Month/Year Filed)	Yes	No
_____	_____	____/____/____	<input type="checkbox"/>	<input type="checkbox"/>
(Application No.)	(Country)	(Day/Month/Year Filed)	Yes	No
_____	_____	____/____/____	<input type="checkbox"/>	<input type="checkbox"/>
(Application No.)	(Country)	(Day/Month/Year Filed)	Yes	No

I/We hereby appoint Gary M. Nath, Reg. No. 26,965; Harold L. Novick, Reg. No. 26,011; Suet M. Chong, Reg. No. 38,104; Todd L. Juneau, Reg. No. 40,669; Gregory B. Kang Reg. No. 45,273; Scott F. Yarnell Reg. No. 45,245; Lee C. Heiman, Reg. No. 41,827; Jerald L. Meyer, Reg. No. 41,194; Paul A. Sacher, Reg. No. 43,418; and David R. Murphy, Reg. No. 22,751, as my attorneys to prosecute this application and transact all business in the U.S. Patent and Trademark Office connected therewith.

Direct Telephone Calls to:

Harold L. Novick  
(202) 775-8383

Send Correspondence to:  
**NATH & ASSOCIATES**  
1030 Fifteenth Street, N.W.  
Sixth Floor  
Washington, D.C. 20005 U.S.A.

I/We hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by 35 U.S.C. § 112, first paragraph, I/we acknowledge the duty to disclose material information as defined in 37 CFR § 1.56 which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

(U.S. Application Serial No.)	(U.S. Filing Date)	(Status--patented, pending, abandoned)
_____	_____	_____
(U.S. Application Serial No.)	(U.S. Filing Date)	(Status--patented, pending, abandoned)
_____	_____	_____

DECLARATION FOR PATENT APPLICATION

Docket No. 82239

PAGE 2

I/We hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements are made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. § 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first inventor: Anil Kumar DWIVEDI

Inventor's Signature \_\_\_\_\_ Date \_\_\_\_\_

Residence: Central Drug Research Institute, Chattar Manzil Palace, Post Box No. 173, Lucknow-226001,  
U.P., India

Citizenship: India

Post Office Address: Same as above

Full name of second inventor: Madhu KHANNA

Inventor's Signature \_\_\_\_\_ Date \_\_\_\_\_

Residence: Central Drug Research Institute, Chattar Manzil Palace, Post Box No. 173, Lucknow-226001,  
U.P., India

Citizenship: India

Post Office Address: Same as above

Full name of third inventor: Wahajul HAO

Inventor's Signature \_\_\_\_\_ Date \_\_\_\_\_

Residence: Central Drug Research Institute, Chattar Manzil Palace, Post Box No. 173, Lucknow-226001,  
U.P., India

Citizenship: India

Post Office Address: Same as above

Full name of fourth inventor: Ram RAGHUBIR

Inventor's Signature \_\_\_\_\_ Date \_\_\_\_\_

Residence: Central Drug Research Institute, Chattar Manzil Palace, Post Box No. 173, Lucknow-226001,  
U.P., India

Citizenship: India

Post Office Address: Same as above

Full name of fifth inventor: Sudhir SRIVASTAVA

Inventor's Signature \_\_\_\_\_ Date \_\_\_\_\_

Residence: Central Drug Research Institute, Chattar Manzil Palace, Post Box No. 173, Lucknow-226001,  
U.P., India

Citizenship: India

Post Office Address: Same as above

DECLARATION FOR PATENT APPLICATION

Docket No. 82239

PAGE 3

Full name of Sixth inventor: Puvvada SRI

Inventor's Signature \_\_\_\_\_ Date \_\_\_\_\_

Residence: Central Drug Research Institute, Chattar Manzil Palace, Post Box No. 173, Lucknow-226001,  
U.P., India

Citizenship: India

Post Office Address: Same as above

Full name of seventh inventor: Ramchandra MURTHY

Inventor's Signature \_\_\_\_\_ Date \_\_\_\_\_

Residence: Central Drug Research Institute, Chattar Manzil Palace, Post Box No. 173, Lucknow-226001,  
U.P., India

Citizenship: India

Post Office Address: Same as above

Full name of eighth inventor: Onkar Prasad ASTHANA

Inventor's Signature \_\_\_\_\_ Date \_\_\_\_\_

Residence: Central Drug Research Institute, Chattar Manzil Palace, Post Box No. 173, Lucknow-226001,  
U.P., India

Citizenship: India

Post Office Address: Same as above

Full name of Ninth inventor: Jagdishwar Sahay SRIVASTAVA

Inventor's Signature \_\_\_\_\_ Date \_\_\_\_\_

Residence: Central Drug Research Institute, Chattar Manzil Palace, Post Box No. 173, Lucknow-226001,  
U.P., India

Citizenship: India

Post Office Address: Same as above

Full name of tenth inventor: Satyawan Singh

Inventor's Signature \_\_\_\_\_ Date \_\_\_\_\_

Residence: Central Drug Research Institute, Chattar Manzil Palace, Post Box No. 173, Lucknow-226001,  
U.P., India

Citizenship: India

Post Office Address: Same as above